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ABSTRACT 
The ubiquitous flavonoid quercetin is broadly recognized for showing diverse biological and health-
promoting effects, such as anti-cancer, anti-inflammatory and cytoprotective activities. The 
therapeutic potential of quercetin and similar compounds for preventing such diverse oxidative 
stress-related pathologies has been generally attributed to their direct antioxidant properties. 
Nevertheless, accumulated evidence indicates that quercetin is also able to interact with multiple 
cellular targets influencing the activity of diverse signaling pathways. Even though there are a 
number of well-established protein targets such as phosphatidylinositol 3 kinase and xanthine 
oxidase, there remains a lack of a comprehensive knowledge of the potential mechanisms of action 
of quercetin and its target space. In the present work we adopted a reverse screening strategy based 
on ligand similarity (SHAFTS) and target structure (idTarget, LIBRA) resulting in a set of predicted 
protein target candidates. Furthermore, using this method we corroborated a broad array of 
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previously experimentally tested candidates among the predicted targets, supporting the suitability 
of this screening approach. Notably, all of the predicted target candidates belonged to two main 
protein families, protein kinases and poly [ADP-ribose] polymerases. They also included key 
proteins involved at different points within the same signaling pathways or within interconnected 
signaling pathways, supporting a pleiotropic, multilevel and potentially synergistic mechanism of 
action of quercetin. In this context we highlight the value of quercetin's broad target profile for its 
therapeutic potential in diseases like inflammation, neurodegeneration and cancer. 
Keywords: drug target prediction; molecular docking; flavonoids; quercetin. 
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1. Introduction 
Phytochemical rich diets are correlated with increased longevity and a wide range of health benefits 
including a decreased incidence of cardiovascular diseases and a slowed progression of 
cerebrovascular diseases (Commenges et al., 2000; McCullough et al., 2012). Flavonoids constitute 
one of the largest families of phytochemicals found in plants. Alongside their contribution to the 
flavor and the color of fruits and vegetables, flavonoids are widely recognized for their direct 
antioxidant properties (Cao et al., 1997; Fuhrman and Aviram, 2001). In particular, many flavonoids 
display anti-inflammatory, anti-carcinogenic, and neuroprotective effects among other bioactivities 
(Arredondo et al., 2010; Spencer 2012; Vidya Priyadarsini et al., 2010). 
This ubiquitous polyphenolic group comprises several subclasses such as flavones (including 
flavonols), flavanones, flavans (including flavanols), isoflavones, chalcones and anthocyanidins. 
Flavonols are by far the most abundant and widely distributed in nature, with quercetin (2-(3,4-
dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one) being a prototypical flavonol. Despite having 
well characterized antioxidant actions, there is an emerging view that the neuroprotective, anti-
inflammatory and anti-cancer effects of flavonoids are likely mediated by interaction with specific 
proteins involved in intracellular signaling cascades (Spencer, 2009; Williams et al., 2004). 
Currently quercetin and related flavonoids are well known phosphatidylinositol 3 kinase (PI3-
kinase), xanthine oxidase and cyclooxygenase inhibitors but beyond these targets, a complete 
understanding of the underlying mechanism of action of quercetin requires the description of its 
whole target space. Modulating multiple targets is potentially more beneficial than a single target in 
terms of overall efficacy, possible side effects, resistance or compensatory mechanisms andsuch a 
multi-modal mechanism of action for quercetin supports its therapeutic potential (Koeberle and 
Werz, 2014). 
While multi-target detection by wet-lab studies such as affinity chromatography, expression cloning 
and protein microarray is work- and time-intensive, in silico target prediction is a valuable 
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inexpensive and complementary approach that could bring an unbiased view of the potential protein 
targets of quercetin (Hart, 2005). ReverseScreen3D, INVDOCK, Tarfisdock, PharmMapper and 
idTarget are some of the in silico target prediction tools available (Cereto-Massagué et al., 2015; 
Koutsoukas et al., 2011). Employing these platforms has led to the identification of protein targets 
for a number of novel bioactive compounds such xyloketal and kinetin as well as for approved 
drugs like mebendazol (Dakshanamurthy et al., 2012; Kumar et al., 2015; Su et al., 2014). For a 
comprehensive review on the topic please refer to (Cereto-Massagué et al., 2015). 
In the present study we propose a hierarchical screening of quercetin protein targets based on the 
sequential arrangement of ligand similarity search, binding site comparison and inverse docking. 
Additionally, a selected set of targets was assessed by means of molecular dynamics simulations 
demonstrating favorable binding with quercetin. Taking together, these approaches resulted in a 
predicted set of protein target candidates that can be related to the biological effects of quercetin. 
Supporting these findings, a broad array of previously proposed quercetin protein targets were 
identified as positive hits in this screening approach validating its utility. Above all, through its 
ADP/ATP mimetic capacity, quercetin might influence several proteins from related signaling 
pathways implying a potentially multilevel and synergistic mechanism of action. 
2. Methods 
2.1 Reverse Screening 
The current in silico strategies for target identification include ligand-based, structure-based, 
machine learning-based and biochemical network-based approaches. When searching for potential 
target proteins in the first case, a query ligand is compared against a library of known interacting 
compounds and protein targets are retrieved by association (Klabunde, 2007). Alternatively, binding 
site comparison relies on the structure similarity between known and unknown protein targets. 
Inverse docking is another structure-based method, contrary to classic docking schemes it screens 
and ranks a protein library instead of a ligand library. 
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The present work followed a hierarchical screening scheme, which took advantage of the fastest 
methods (ligand similarity and binding site comparison) in its first stages to reduce the search space 
for the most expensive approach (docking) and to reduce the number of false positives obtained 
(Kumar and Zhang, 2015). For each step in the screening we chose three of the most recent publicly 
available software’s for in silico target prediction (Fig. 1), also including protein candidates with 
similar binding site recognized by our in-house-developed software LIBRA (Ligand Binding Site 
Recognition Application) (Hung et al., 2015). 
2.1.1 The ligand-target database 
A database of suitable ligands contained in the Protein Data Bank was developed for ligand-based 
screening (Berman, 2000). Firstly, all the ligands contained in the PDB were downloaded from the 
2014 version of LigandExpo database, a repository for co-crystalized structures and hetero-atoms in 
general indexed with the corresponding protein entry (Feng et al., 2004). The molecular structures 
were downloaded in SMILES-Stereo format as a whole database and rebuilt in Molecular Operating 
Environment (MOE) software (Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite 
#910, Montreal, QC, Canada, 2011). Starting from 17969 PDB ligand entries, a series of 
hierarchical filters were applied with MOE to construct the database as follows: 1) Hydrogenation 
was corrected; 2) Undesirable small molecular weight ligands (salts and water molecules) and 
repeated entries were removed; 3) Molecules below the molecular weight of the flavonoid frame 
were deleted and Oprea rules were applied to restrict the database to flavonoid-like molecules and 
drug-like molecules respectively. Oprea rules are a refined version of the classical Lipinski's rules 
of five to determine drug likeliness (Oprea et al., 2007); 4) Molecules containing Se or As were also 
deleted. The current molecular database was energy minimized in MOE with a Merck molecular 
force field (MMFF94x) until 0.01 kcal/mol RMS gradient and saved in mol2 format. The final 
database contained 9924 different molecules. 
2.1.2 Ligand-based screening of quercetin 
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Taking quercetin as a probe, we searched our in-house ligand-target database for similar co-
crystallized ligands in the PDB. Quercetin molecular structure was built in MOE, energy minimized 
(MMFF94x, 0.01 kcal/mol RMS gradient) and saved in mol2 format for screening processes. 
SHAFTS (SHApe-Feature Similarity) algorithm implemented in its stand-alone version was used to 
screen quercetin against the conformers obtained from the ligand-target database. SHAFTS is an 
algorithm for tridimensional structural similarity calculation and ligand-based virtual screening (Liu 
et al., 2011). SHAFTS has been validated with decoy benchmark datasets and has demonstrated 
satisfactory active compounds enrichment and scaffold hopping capability against several 
representative kinases in retrospective virtual screening studies (Bai et al., 2012; Kong et al., 2012; 
Liu et al., 2011; Lu et al., 2011). It adopts a similarity metrics considering both molecular shape and 
pharmacophoric characteristics (hydrophobic center, positive or negative charge center, hydrogen 
bond acceptor and donor, and aromatic rings). A feature triplet hashing method is used for the fast 
rigid alignment of molecular structure. It finally returns a sorted list of molecule identifiers 
associated with structural similarity score against the query and the corresponding structural 
alignment. 
Because SHAFTS uses a semi-rigid strategy for structural alignment, the conformational analysis 
program Cindy was used to generate a maximum of 100 lowest-energy conformers for each 
molecule in the ligand-target database (Liu et al., 2009). SHAFTS was then implemented with its 
default configuration. Protein complex identifiers were retrieved for ligands with a similarity score 
against quercetin above 1.5 (maximum 2.0) and subjected to the next stage of the screening. 
2.1.3 Target candidate amplification based on binding site similarity 
Delineating binding site similarities for proteins is another possible route for finding new targets for 
existing ligands. The protein candidates selected by SHAFTS were subjected to binding site 
comparison against a representative set of proteins contained in the PDB using our in-house-
developed software LIBRA[RW1] (Hung et al., 2015). LIBRA is a tool for searching local structural 
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similarities between a protein structure and a collection of functional sites and their environment. It 
employs a graph-based approach in conjunction with a database of more than 170 thousand ligand 
binding sites generated by extracting residues surrounding the ligand from approximately 75 
thousand structures of protein-ligand complexes deposited in PDB. Similar sites were defined 
according to these requirements: 100 % of similar residues (blosum62 scoring), minimum motive 
size of 5 residues, maximum structural alignment RMSD of 1 Å (Ångström) and no steric clashes 
between the ligand from the query protein and the known protein. 
2.1.4 Structure-based screening 
The optimized structure of quercetin was uploaded onto the online inverse dock server idTarget for 
screening against the selected list of protein candidates obtained in the previous stage. 
idTarget performs inverse molecular docking for a query molecule against the whole PDB or a 
custom list of protein structures (Wang et al., 2012). It applies a divide and conquer algorithm to 
search the protein surface for suitable docking sites and a state-of-the-art scoring function optimized 
for binding energy prediction and evaluated with external decoy sets (Wang et al., 2012, 2011). A 
protein target i for a ligand j is selected considering the affinity profile for the ligand. Analogously 
to the use of docking decoys a Z-score is calculated according to: Zij=(Eij–Ei)/sdi, where Eij is the 
dock score of ligand j to the protein pocket i, Ei and sdi are the center and width of the affinity 
profile of protein i. 
We selected the server scanning mode as it is the most exhaustive, where usual molecular docking 
procedures are carried out for each protein structure. Proteins were considered to be possible ligand 
targets if the idTarget binding energy was lower than -9.0 kcal/mol (250 nM predicted affinity) with 
a Z-score of 1.0 or lower (adapted from (Nikolić et al., 2015)). 
In order to assess the reliability of the results, docking studies were also performed using MOE 
against target candidates. Protein candidate crystallographic structures were retrieved from the PDB 
as its biological unit. Each structure was optimized before analysis, hydrogen atoms were adjusted 
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and charges assigned with Amber12 force field, missing loops and atoms were completed by 
structure preparation module. For docking purpose, binding sites were defined by the corresponding 
co-crystallized ligand, and co-factors were included as part of the receptor if present. Default 
docking parameters were used such as Triangle Matcher Algorithm with London dG (scoring) and 
GBVI/WSA-dG (re-scoring) functions to generate 10 poses of each ligand.  It should be taken into 
account that for the docking strategy, the solvent was not considered explicitly but using a scoring 
function in which the desolvation was calculated in an empirical way. 
2.2 Molecular dynamics simulations of quercetin-target candidate complexes 
Molecular dynamics (MD) simulations used the Nose Poincare Anderson (NPA) method 
implemented in MOE. The constant number of particles, volume, and temperature (NVT) ensemble 
with T) 300 K was used. The complex was immersed in a periodic water box with 6 Å margin with 
neutralizing ions (NaCl), and the whole system minimized to 1 kcal/mol RMS gradient before 
starting the MD run. Prior to the main simulation of 10 ns, a 100 ps stage gradually heated the 
molecular system to 300 K. Between the heating stage and main simulation the system velocities 
were reassigned which can improve sampling (Su et al., 2015). The interaction potential energy 
between the atoms of the ligand and the rest of the system was registered along the simulation and 
quercetin interactions were assessed by MOE PLIF module with default parameters. Equilibration 
was monitored by convergence in terms of the temperature, energy, and the RMSD (root-mean-
squared deviations) of the backbone atoms as compared to the crystal structure of both complexes. 
2.3 Functional annotation of protein target candidates 
The final set of protein candidates was annotated according to protein structure and family, activity 
and involvement in disease. The corresponding human homologue was taken for proteins belonging 
to other mammals. The information was obtained from different sources including publicly 
available databases and tools like PDB, Uniprot (Consortium, 2014), DAVID (gene ontology terms 
and literature information) (Dennis et al., 2003), KEGG (biological pathways) (Kanehisa and Goto, 
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2000), GO TermMapper (gene ontology terms) (Boyle et al., 2004; Harris et al., 2004) and FlyMine 
(gene ontology terms and literature information) (Lyne et al., 2007) which bring complementary 
data. In addition, molecular targets identified by different approaches can be mapped onto specific 
disease-associated networks or pathways and target databases to construct protein-protein 
interaction networks. The “Search Tool for the Retrieval of Interacting Genes/Proteins” (STRING) 
database integrates information about interactions of proteins from different types of databases and 
was used for this purpose (Kuhn et al., 2012). 
3. Results and discussion 
3.1 Reverse screening 
3.1.1 Ligand-based screening of quercetin 
Using quercetin as an input molecule for SHAFTS algorithm we screened a database of 
pharmacologically relevant ligands associated with protein complexes in the PDB. Quercetin-like 
compounds were selected based on SHAFTS similarity score obtaining a list of 34 molecules  
which share the typical flavonoid scaffold with the exception of those identified by PDB as FL9, 
PIT, RE2, SLX, STL and DEH (see Table 1 from supplementary material). The corresponding co-
crystallized protein set comprised 25 mammalian proteins. Proteins from plants and other organisms 
were not considered for the subsequent analysis. 
3.1.2 Binding site comparison 
Based on LIBRA analysis on local similarity at the protein binding site we conducted an 
amplification stage of the candidates found by ligand-based screening. Interestingly, most of the 
proteins identified also bind ligands with some similarity to quercetin and can be found in the first 
screening stage with a SHAFTS score ranging from 1.0 to 1.3 (see Table 2 from supplementary 
material). Such consistency between both approaches suggests that additional reliable candidates 
could have been initially found with a less stringent cut-off ligand based screening. 
Along with the previous set of candidates three main protein classes can be distinguished, 
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sulfotransferases, tankyrases-poly(ADP-ribosyl)transferases and kinases. Most of these kinases 
share the same fold according to PFAM, the protein kinase domain (PF00069) followed by the 
tyrosine kinase domain (PF07714). Another kinase domain present in the candidate dataset is the 
PI3-kinase domain (PF00613) corresponding to the well-known quercetin target 
phosphatidylinositol 3 kinase (Walker et al., 2000). 
3.1.3 Structure-based screening 
From the previous screening stages, a list of 74 protein target candidates was identified. This set of 
proteins was then subjected to structure-based screening against quercetin using idTarget. This 
procedure allowed us to obtain protein target candidates associated with docking poses for quercetin 
and ranked according to their predicted affinity (see Tables 3 and 4 from supplementary material). 
The predicted affinity ranges from 15.1 nM to 494.1 nM, and has minor variations depending on the 
specific crystal structure for a given protein. From the unranked set idTarget server only rejected 1 
mammalian protein, sirtuin 5, which confirms the reliability of the molecular similarity comparison. 
It is also remarkable that all known complexes for quercetin available in the PDB at the time of the 
assay were retrieved. 
According to the docking poses obtained by idTarget, quercetin reaches a known binding site of 
every protein which is generally a catalytic or an allosteric site (Fig. 2). While idTarget accurately 
predicted protein binding sites, docking poses did not always resemble the co-crystallized ligand 
orientation. Frequently quercetin appeared in the same plane but with opposite orientation. This 
divergence can be explained by the quercetin inner symmetry. Additionally, a small number of 
docking simulations showed peculiarities, for example a few sirtuin 3 docking poses overlapped 
with the protein substrate, glycogen phosphorylase docking poses were located in a known 
allosteric site normally occupied by the endogenous ligand AMP, sulfotransferases and ATPase 
docking poses could also bind the ATP site proximal to an allosteric site. Except for 
sulfotransferases all these proteins showed unfavorable Z-scores and predicted affinities. Proteins in 
11 
this latter group have wide and exposed binding sites in contrast with the best scoring candidates. 
According to idTarget score and taking into account the qualitative considerations expressed above, 
proteins such as macrophage migration inhibitory factor, troponin C, transthyretin, and ATP 
synthase among others should not be prioritized as target candidates. 
An interesting finding of the present study is that most of the endogenous ligands, substrates or 
cofactors related to the resulting protein set are nucleotide derivatives like ATP/ADP, FAD, NAD, 
pyridoxal phosphate, PAPS, PAP, HIBYL-CoA and xanthine. The protein target candidates greatly 
vary in sequence length, fold and quaternary structure, meaning that any structural similarity found 
among them might be rather local than global. In the first instance, structural similarity between 
quercetin and ATP/ADP was thus analyzed. The result of this analysis (Fig. 3) indicated that 
quercetin may work as an ATP mimetic. In this regard, previous studies suggested a correspondence 
between the benzopyranone moiety of the flavonoid and the adenine part of the ATP as well as the 
ortho-dihydroxyphenyl and the phosphates of ATP (Teillet et al., 2007). 
Additionally, a comparison between idTarget score and MOE score is depicted in Fig. 4 showing a 
rough but significant agreement between both systems (p-value < 0.0001) supporting idTarget 
screening. MOE docking incorporates GBVI/WSA dG, a forcefield-based scoring function which 
estimates the free energy of binding of the ligand from a given pose as well as the solvation effect 
and allows the explicit representation of co-factors and substrates in the vicinity of the binding site 
which supposed an improvement of idTarget results. 
3.2 Molecular dynamics simulations of quercetin-target candidate complexes 
Taking into consideration their biological relevance we evaluated a selected group of protein 
candidates by means of molecular dynamics. This is a more realistic approach that allows the 
dynamic behavior of a system and the explicit influence of solvent molecules to be addressed as 
would occur in a living organism. 
The following quercetin-protein complexes were generated: glycogen synthase kinase-3 beta (GSK-
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3b) from 1j1b crystal, mitogen-activated protein kinase 14 (MAPK14) from 3s3i crystal, 
phosphatidylinositol 3-kinase gamma (PI3K) from 1e8w crystal, and poly [ADP-ribose] polymerase 
1 (PARP) from 3gjw crystal. For MAPK14 a different crystal was chosen from the one identified in 
the screening due to a missing loop in the structure that could not be correctly completed in MOE. 
Three 10 ns simulations were run for each system in a periodic water box at 300 K. Ramachandran 
plots indicated that phi/psi dihedral angles of each protein chain generally remained under allowed 
regions with few exceptions located nearby. Each system showed an initial divergence from the 
starting point of around 1 Å measured at backbone atoms (see Table 5 from supplementary 
material). Frames along the simulation had a divergence of around 0.5 (not shown). Total potential 
energy and interaction potential energy measured along the simulation indicated a homogeneous 
behavior of the systems and showed that quercetin was stabilized in the protein binding site (see 
Fig. 1 to 3 from supplementary material). The average values of three 10 ns simulations measured 
from the last ns were -98,4 kcal for GSK-3b, -112,3 kcal for MAPK14, -123,1 kcal for PI3K and -
113,8 kcal for PARP1. A characteristic interaction pattern was observed involving residues with 
hydrogen donating or accepting moieties like glutamate, aspartate and serine (Fig. 5). It was the 
receptor protein which contributed with most of the interaction energy through hydrogen-donating 
and accepting groups and to a lesser extent aromatic residues and also showed an explicit 
involvement of water molecules in the binding. Solvent contribution with the interaction energy 
grows from around 15 % in the case of PI3K, 30 % in PARP1 and MAPK14 complexes and 40 % in 
GSK-3b. Another major feature of quercetin interaction is the participation of the different hydroxyl 
groups, being substitutions in positions 3', 4' and 7 those which were generally involved in direct 
contacts with the target. Interestingly these feature are shared by other polyphenols like resveratrol 
with similar biological effects documented. 
3.3 Functional characterization 
The ranked candidate set comprises proteins with a broad range of macromolecular folds and 
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biological activities including enzymes, transcription factors and transporters, and can be divided 
into proteins with direct metabolic action like xanthine oxidase and proteins involved in 
intracellular signaling pathways. The significantly enriched gene ontology (GO) functional 
annotations of quercetin target candidates include regulation of cell death and proliferation and 
KEGG pathways highlight their involvement in cancer and neurodegeneration (annotations 
incorporated in Table 1). The role of some target proteins in neuronal physiology is also notable, 
given their involvement in neurotrophin signaling, neuronal differentiation and synapse function 
(not shown). These correspond with already reported effects of flavonoids (Blasina et al., 2009; 
Chen et al., 2015; Spencer, 2009). STRING protein-protein interaction network analysis illustrates 
many functional associations among the target candidates supporting their participation in related 
biological processes (Fig. 6).  
Remarkably, there is a wide array of predicted proteins like tyrosine protein kinase Src, casein 
kinase 2 and vascular endothelial growth factor receptor 2 which have been tested by experimental 
assays supporting their interaction with quercetin and/or related flavonoids like myricetin, apigenin 
and luteolin (Table 2). Furthermore, among the predicted candidates, experimentally tested and 
untested proteins behaved equally in terms of docking scores having no statistically significant 
difference (t-test). On the whole the predicted target candidates are associated with a spectrum of 
biological activities that is in agreement with the multi-target mechanism of action proposed for 
quercetin (Table 1). Considering the underlying structural similarities, being kinases and PARPs the 
two main protein folds involved, it is safe to assume the predicted candidates constitute a whole 
group of quercetin protein targets. Predicted candidates that have not previously been reported 
could be of interest for drug discovery and future target validation. 
Protein kinases should be highlighted, a number of which have been recognized as promising drug 
targets for tumor therapy and neurodegeneration including MAP kinases, receptor tyrosine kinases, 
and kinases related to the PI3-kinase/Akt/mTOR signaling pathway (Han et al., 2015; Sebolt-
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Leopold and Herrera, 2004; Zhang et al., 2015; Zhou and Huang, 2012). For example, p38 MAPK 
is a key protein kinase involved in neuronal apoptosis and inflammation, whose inhibition has been 
proposed as a treatment against ischemic damage and neurodegeneration (Zhang et al., 2015). In 
this regard, previous studies have shown that quercetin treatment leads to pro-apoptotic effects in 
cancer models through modulation of these kinase pathways (Russo et al., 2014). Thus, our results 
are in agreement with such proposed quercetin effect. 
Another interesting group is that of Tankyrases, which are a particular group of poly(ADP-
ribosyl)transferases that differ by their overall domain structure and functions. It has been suggested 
that tankyrase inhibitors could improve anti-cancer effects if combined with other kinase inhibitors 
such as MEK, epidermal growth factor receptor or PI3-kinase inhibitors in cancer treatment (Lehtiö 
et al., 2013). PARP-1 is also related to kinase signaling. PARP-1 facilitates diverse inflammatory 
responses by promoting inflammation-relevant gene expression through NF-kappaB and promotes 
mitochondria-associated cell death in injured tissues (Ba and Garg, 2011). It is widely accepted that 
PARP-1 signals to the MAPK pathway by modulating the phosphorylation of ERK1/2, p38, and c-
Jun NH2-terminal kinase. Thus far, studies on the relationship between PARP-1 and MAPK suggest 
that they might stimulate each other in a positive feedback cycle to propagate the responses to long-
lasting stress signals (Ba and Garg, 2011). Such crosstalk between protein targets reinforces the 
concept of multilevel and synergistic mechanisms of action underlying the biological effects of 
flavonoids. 
Another relevant point is the pleiotropism of many of the protein targets in both cancer and 
neuroprotection. Glycogen synthase kinase 3b is a perfect example of a promising target candidate 
which is involved in cancer survival and also promotes nuclear export and degradation of Nrf2 
(Nuclear Factor-erythroid 2 (NF-E2) p45-related Factor-2), a transcription factor that triggers 
antioxidant and cytoprotective responses (Jain and Jaiswal, 2007; Russo et al., 2014; Yoshino and 
Ishioka, 2015). 
15 
The metabolism of polyphenols is also suggested by the presence of oxidoreductases and 
sulfotransferases like sulfotransferase 1B1 and NRH dehydrogenase [quinone] 2 (NQO2). The 
latter, apparently serves as a quinone reductase in connection with conjugation reactions of 
hydroquinones involved in detoxification pathways. NQO2 inhibition by quercetin (experimental 
Kd = 50 nM) resveratrol (Kd = 30 nM) and other polyphenols was suggested to have a role in the 
induction of antioxidant defenses that could underly their long term chemopreventive effects 
(Buryanovskyy et al., 2004). Whether this enzyme activity is simply limited to polyphenol excretion 
or also to the production of biologically active molecules is currently unclear. 
Thereis remarkable similarity between quercetin, resveratrol and other flavonoids which share 
common pharmacophoric features. In accordance with the underlying hypothesis of this work, the 
target profile of quercetin may not be specific and could be generalized. For instance docking scores 
between target candidates and related flavonoids extracted from PubChem with a Tanimoto 
similarity of 98 % like myricetin and fisetin showed in general a difference below 5 % from 
quercetin. 
Flavonoids have been widely studied for their in vitro free radical scavenging activity considering it 
a property that could prevent or delay the onset of oxidative stress related diseases. However, this 
mechanism of action presents many difficultiessuch as kinetic limitations and the fact that many 
endogenous antioxidants are present at much higher concentrations. In thisstudy we shed light, in an 
unbiased way, on the potential protein targets of quercetin that could underlie its wide ranging 
biological effects. In light of these considerations and the known involvement of protein targets like 
kinases and PARPs in disease, the polypharmacological profile of quercetin and related flavonoids 
could be very relevant reinforcing their therapeutic potential. 
Even though most multi-target drugs have been discovered serendipitously, rationally designed 
multi-target directed drugs have shown promising results (Bolognesi and Cavalli, 2016). Indeed, in 
addition to quercetin described here, several drugs are known to modulate multiple targets, and this 
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polypharmacological property could underlie therapeutic efficacy (Talevi, 2015). Another 
potentially favorable feature is that a weak-binding molecule acting on multiple targets can 
potentially deliver the same outcome as a high-affinity drug acting on a single target (Wang et al., 
2016).  Moreover, promiscuous, or multi-target drugs, have a higher likelihood of successfully 
modulating whole cellular networks in diseases driven by multiple pathological processessuch as 
cancer and neurodegeneration. Despite this, and even though dietary derived compounds are 
generally recognized as safe, it must be considered that different target profiles could lead to 
positive or negative effects depending largely on drug dose. How to fine-tune different antagonistic 
effects for maximal efficacy is an important and emerging area of research (Prati et al., 2016; Wang 
et al., 2016). 
4. Conclusions 
In conclusion, in this study, a hierarchical inverse screening approach using SHAFTS-LIBRA and 
idTarget was employed to identify potential protein targets of quercetin. The screening successfully 
retrieved every quercetin target contained in the PDB including phosphatidylinositol 3-kinase, 
xanthine oxidase and expanded the list to new putative quercetin targets like poly(ADP-ribose) 
polymerases. Most of the predicted panel of targets fall under recognized clinical targets with anti-
tumour and neuro-protective effects or target enzymes of drug design such as glycogen synthase 
kinase-3 beta and mitogen-activated protein kinase 14, and some of them have been well 
established in experimental settings. In addition, some of these protein targets are involved at 
different stages within the same signaling pathways or in interconnected signaling pathways, 
supporting a pleiotropic, multilevel and synergistic mechanism of action of quercetin. Above all the 
predicted targets could be grouped in two main groups comprised of protein kinases and PARPs. 
These protein groups established similar interactions with quercetin that persisted during molecular 
dynamics simulations. These results support the hypotheses that quercetin is a multi-kinase and 
multi-PARP inhibitor that could act synergistically. PARP-1 as a stress sensor is a potential 
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therapeutic target in pathologies like cancer, inflammation related diseases and neurodegenerative 
diseases (Martire et al., 2015). Indeed, multi-kinase inhibitors are a promising therapeutic approach 
for many pathologies like cancer and viral infections, with imatinib, desatinib and staurosporine as 
examples (Broekman, 2011; Carra et al., 2013; Kruse et al., 2011; Martinez-Gil et al., 2013). Above 
all, the interactions described hereconstitute a potential explanation for the multiple and diverse 
biological effects documented by epidemiological, in-vivo and in-vitro studies of quercetin and 
related flavonoids. 
However, some issues still need to be addressed. Apart from docking scoring limitations in protein-
target ranking, the under representation of rare proteins in the PDB or the absence of proteins for 
which three-dimensional structures are not available can cause false negatives (Warren et al., 2006; 
Xie and Bourne, 2005). In addition, to further refine these results other interaction repositories like 
DrugBank could be incorporated. Additional validation of the results for some target candidates can 
also be achieved by explicitly using docking benchmark data-sets (decoys) (Bauer et al., 2013; 
Huang et al., 2006). Moreover, the interactions of more ligand-protein complexes could also be 
analyzed by means of molecular dynamics simulations to ensure that flexibility of proteins and 
solvent effects are considered. 
In conclusion, reverse screening approaches describes a different workflow to provide valuable 
information for future in vitro and in vivo studies with flavonoids or, in general, for drug discovery. 
Overall, the present results may broaden the understanding of the mechanisms of action of quercetin 
and generate new hypotheses about its therapeutic potential, allowing a repositioning of quercetin 
and quercetin analogues for potential future therapeutic developments. 
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Tables 
Table 1 
Disease association and relevant biological process for the target candidates found in the Protein 
Data Bank (PDB). 
Uniprot id Name Associated disease Biological process Class 
Homo sapiens
Q00534 Cyclin dependent kinase 6 Cancer  Cell cycle/transferase
Q9H2K2 Tankyrase-2   Transferase/transferase inhibitor
P49888 Estrogen sulfotransferase Cancer  Transferase
O75897 Sulfotransferase 1C4   Transferase
O00338 Sulfotransferase 1C2 Cancer  Transferase
P50225 Sulfotransferase 1A1 Cancer  Transferase
O43704 Sulfotransferase family cytosolic 1B member 1   Transferase 
P09960 Leukotriene A-4 hydrolase Immune diseases  Hydrolase
P49759 Dual specificity protein kinase CLK1  Proliferation Transferase 
P0DMM9 Sulfotransferase 1A3 Cancer  Transferase
P35968 Vascular endothelial growth factor receptor 2 Cancer 
Cell 
death/proliferation 
Transferase/transferase 
inhibitor
P16083 NRH dehydrogenase [quinone] 2 Cancer, Parkinson's disease  Oxidoreductase 
Q13554 Calcium/calmodulin-dependent protein kinase type 2 beta Cancer 
Cell death/neuron 
related Transferase 
O95271 Tankyrase-1   Transferase/transferase inhibitor
Q6IMI6 Sulfotransferase 1C3   Transferase
Q13627 
Dual specificity tyrosine-
phosphorylation-regulated kinase 
1A 
  Transferase 
Q460N3 Poly [ADP-ribose] polymerase 15   Transferase 
Q460N5 Poly [ADP-ribose] polymerase 14   Transferase 
P09874 Poly [ADP-ribose] polymerase 1 Alzheimer's disease  Transferase/transferase inhibitor
O60674 Tyrosine-protein kinase JAK2 Cancer 
Cell 
death/proliferation/n
euron related 
Transferase/transferase 
inhibitor 
P68400 Casein kinase 2 subunit alpha Parkinson's disease  Transferase
Q9NZL9 Methionine adenosyltransferase 2   Oxidoreductase
25 
subunit beta 
P15056 Serine/threonine-protein kinase B-raf Cancer 
Cell 
death/proliferation/n
euron related 
Transferase/transferase 
inhibitor 
Q9UGN5 Poly [ADP-ribose] polymerase 2  Cell death Transferase
O14965 Aurora kinase A Cancer Cell death/neuron related 
Transferase/transferase 
inhibitor
P23458 Tyrosine-protein kinase JAK1 Cancer Proliferation Transferase/transferase inhibitor
O43293 Death-associated protein kinase 3 Cancer Cell death/neuron related Transferase 
P11362 Fibroblast growth factor receptor 1 Cancer 
Cell 
death/proliferation/n
euron related 
Transferase/transferase 
inhibitor 
Q96RR4 Calcium/calmodulin-dependent protein kinase kinase 2 Anxiety disorder  
Transferase/transferase 
inhibitor
P49841 Glycogen synthase kinase-3 beta Alzheimer's disease, cancer 
Cell death/neuron 
related Transferase 
O94768 Serine/threonine-protein kinase 17B  Cell death Transferase 
O14757 Serine/threonine-protein kinase Chk1 Cancer Proliferation Transferase 
P24941 Cell division protein kinase 2 Cancer  Transferase
P51813 Cytoplasmic tyrosine-protein kinase BMX  
Cell 
death/proliferation 
Transferase/transferase 
inhibitor
P52333 Tyrosine-protein kinase JAK3  Cell death/proliferation Transferase 
Q16539 Mitogen-activated protein kinase 14 
Parkinson's disease, 
Amyotrophic Lateral 
Sclerosis 
Cell death, neuron 
related 
Transferase/transferase 
inhibitor 
P45983 Mitogen-activated protein kinase 8 
Cancer, Parkinson's 
disease 
Cell death, neuron 
related 
Transferase/transferase 
inhibitor
P08631 Hematopoetic cell kinase HCK Immune diseases, Parkinson's disease Cell death Transferase 
P12931 Proto-oncogene tyrosine-protein kinase Src Cancer 
Cell 
death/proliferation/n
euron related 
Tyrosine-protein kinase 
P50750 Cell division protein kinase 9  Proliferation Transferase
O14936 Peripheral plasma membrane protein CASK Microcephaly Proliferation Transferase 
P37231 Peroxisome proliferator-activated receptor gamma 
Diabetes, Cancer, 
Alzheimer's disease, 
Huntington's disease 
Cell death Transcription regulation 
Q9Y6E0 Serine/threonine-protein kinase 24  
Cell death/neuron 
related Transferase 
P21802 Fibroblast growth factor receptor 2 Cancer 
Cell 
death/proliferation/n
euron related 
Transferase 
P11309 Serine/threonine-protein kinase  Cell death Transferase
26 
PIM-1 
O15530 Phosphoinositide-dependent kinase-1 Cancer 
Cell death/neuron 
related Transferase 
P00519 Tyrosine-protein kinase ABL1 Cancer 
Cell 
death/proliferation/n
euron related 
Transferase 
P06239 Tyrosine-protein kinase LCK Diabetes 
Cell 
death/proliferation/n
euron related 
Transferase 
Q08881 Tyrosine-protein kinase ITK/TSK Immune diseases Proliferation Transferase/transferase inhibitor
Q9H0J9 Poly [ADP-ribose] polymerase 12   Transferase 
P45984 Mitogen-activated protein kinase 9 Cancer 
Cell death/neuron 
related Transferase 
Q8N5Y8 Poly [ADP-ribose] polymerase 16  Cell death 
Transferase/transferase 
inhibitor
Q6NVY1 3-Hydroxyisobutyryl-CoA hydrolase   Hydrolase 
P29320 Ephrin type-A receptor 3  Neuron related Transferase
P14174 Macrophage migration inhibitory factor 
Immune diseaases, 
Alzheimer's disease Cell death Isomerase 
P63316 Troponin C, slow skeletal and cardiac muscles  Cell death Contractile protein 
Q13464 Rho-associated protein kinase 1 Cancer Cell death/neuron related Transferase 
Q99683 Mitogen-activated protein kinase kinase kinase 5 
Amyotrophic Lateral 
Sclerosis 
Cell death/neuron 
related 
Transferase/transferase 
inhibitor
P49137 MAP kinase-activated protein kinase 2  Neuron related Transferase 
P53779 Mitogen-activated protein kinase 10 
Epileptic 
encephalopathy Neuron related 
Transferase/transferase 
inhibitor
O00311 Cell division cycle 7-related protein kinase  Proliferation Transferase 
P04746 Pancreatic alpha-amylase Alzheimer's disease, Parkinson's disease  
Hydrolase/hydrolase 
inhibitor
P02766 Transthyretin Amyloidosis  Transport protein
Q9Y6F1 Poly [ADP-ribose] polymerase 3 Cancer  Transferase/transferase inhibitor
Q9NTG7 NAD-dependent protein deacetylase Sirtuin-3 Aging  
Hydrolase/hydrolase 
inhibitor
Q53GL7 Poly [ADP-ribose] polymerase 10  Proliferation Transferase 
     
Mus musculus  
P54763 
(P29323) Ephrin type-B receptor 2 Cancer  Transferase 
     
27 
Rattus norvegicus  
P63086 
(P28482) 
Mitogen-activated protein kinase 
1 
Alzheimer's disease, 
cancer 
Cell 
death/proliferation/n
euron related 
Transferase 
     
Oryctolagus cuniculus  
P00489 
(P11217) 
Glycogen phosphorylase, muscle 
form   
Transferase/transferase 
inhibitor
     
Sus scrofa  
O02697 
(P48736) 
Phosphatidylinositol 3-kinase 
catalytic subunit Aging, Cancer 
Cell death, neuron 
related 
Phosphoinositide 3- 
kinase gamma
     
Bos taurus  
P80457 
(P47989) 
Xanthine 
dehydrogenase/oxidase  Cell death Oxidoreductase 
Q28021 
(O75116) Rho-associated protein kinase 2 Cancer 
Cell death/neuron 
related Transferase 
P19483 
(P25705) ATP synthase 
Alzheimer's disease, 
Parkinson's disease, 
Huntington's disease 
 Hydrolase 
     
Candidate proteins are segregated by source organism and depicted according to the corresponding 
Uniprot entry (human homologue in parenthesis), name, PDB class, related disease and biological 
process. Proteins co-crystallized with quercetin are depicted in bold. The information was gathered 
from publicly available databases like PDB, Uniprot and gene ontology repositories (Berman, 2000; 
Consortium, 2014; Dennis et al., 2003). 
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Table 2 
Experimental assays supporting quercetin target candidates. 
Name PubChem BioAssay AID; PDB Literature
Cyclin dependent kinase 6 242481, 109522, 1095229, 1224758  
Tankyrase-2 735784 (apigenin, luteolin)  
Estrogen sulfotransferase 747  
Dual specificity protein kinase CLK1 382, 1224761 Reference (Boly et al., 2011)
Vascular endothelial growth factor receptor 2 1063038 Reference (Pratheeshkumar et al., 2012)
NRH dehydrogenase [quinone] 2  Reference (Buryanovskyy et al., 2004)
Calcium/calmodulin-dependent protein kinase 
type 2 beta 673630, 353599, 1224752 
Reference (Boly et al., 
2011)
Tankyrase-1 735786 (apigenin, luteolin)  
Dual specificity tyrosine-phosphorylation-
regulated kinase 1A 
588345 (myricetin), 504441 (kaempferol, 
luteolin), 588345 (keampferol)  
Poly [ADP-ribose] polymerase 1 735783 (apigenin, luteolin)  
Tyrosine-protein kinase JAK2  Reference (Boly et al., 2011)(Luo et al., 2016)
Casein kinase 2 subunit alpha 353598, 378676, 435640, 587344 Reference (Lolli et al., 2012)
Aurora kinase A  Reference (Boly et al., 2011)
Tyrosine-protein kinase JAK1 1224770 
Reference (Boly et al., 
2011)(Kumamoto et al., 
2009)
Death-associated protein kinase 3 1224767  
Fibroblast growth factor receptor 1 378675 (apigenin)  
Calcium/calmodulin-dependent protein kinase 
kinase 2 1224756  
Glycogen synthase kinase-3 beta 1115335, 1224769, 512292, 512292  
Serine/threonine-protein kinase 17B PDB: 3LM5  
Serine/threonine-protein kinase Chk1 512298  
Cell division protein kinase 2 298693, 1224757  
Tyrosine-protein kinase JAK3  Reference (Boly et al., 2011)
Mitogen-activated protein kinase 14 512278, 512278, 603838  
Mitogen-activated protein kinase 8 512277, 603841, 512277  
Hematopoetic cell kinase HCK PDB: 2HCK  
Proto-oncogene tyrosine-protein kinase Src 420260; 1063039  
Peroxisome proliferator-activated receptor 
gamma 
517390, 743191, 439367, 439368, 439367, 
439368 (pathway assays)  
Fibroblast growth factor receptor 2  Reference (Boly et al., 
29 
2011)
Serine/threonine-protein kinase PIM-1 
393, 418378, 706714, 257081, 1063041, 
257081, 311148, 257079, 257080, 257082, 
1224786, 257079; PDB: 4LMU 
Reference (Boly et al., 
2011) 
Phosphoinositide-dependent kinase-1 1224785; 512288  
Tyrosine-protein kinase ABL1 588664 (myricetin) Reference (Boly et al., 2011)
Tyrosine-protein kinase LCK 378681, 512297, 512297  
3-Hydroxyisobutyryl-CoA hydrolase PDB: 3BPT  
Mitogen-activated protein kinase kinase kinase 5 515, 1224773  
MAP kinase-activated protein kinase 2 512283  
Mitogen-activated protein kinase 10 530  
Transthyretin 1239060 (apigenin, luteolin), 1239061 (apigenin, luteolin)  
Mitogen-activated protein kinase 1 512276, 512276  
Phosphatidylinositol 3-kinase catalytic subunit 1185177, 325654, 378677, 1120054; PDB: 1E8W  
Xanthine dehydrogenase/oxidase 
1185460, 1185463, 42472, 424718, 424725, 
424721, 424722, 424735, 424736, 424727, 
424729, 424723, 424734, 424719, 424720, 
424724, 424728, 424730, 1238320, 424718, 
424723, 424725, 424734; PDB: 3NVY 
 
Rho-associated protein kinase 2 512293; 512293  
ATP synthase 338025, 338026; PDB: 2JJ2  
   
   
Bio-assay information was gathered from PubChem and PubMed repositories, tested targets are 
presented along the PubChem assay ID and/or associated publication. Protein co-crystallized with 
quercetin were are also included. 
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Figures 
 
Fig. 1. Reverse screening work-flow. The strategy involved a similarity search with SHAFTS 
(SHApe-Feature Similarity) algorithm of co-crystalized ligands from the Protein Data Bank (PDB) 
(Liu et al., 2011).  An amplification stage is added to identify related proteins by LIBRA (Ligand 
Binding site Recognition Application) binding site comparison (Hung et al., 2015). Finally, protein 
candidates are submited to reverse docking with idTarget web server 
(http://idtarget.rcas.sinica.edu.tw/) (Wang et al., 2012). 
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Fig. 2. Result of quercetin (yellow sticks) molecular docking with mitogen-activated protein kinase 
14 (p38 MAP kinase) co-crystallized with naringenin (violet sticks) (Protein Data Bank accession id 
4eh3) according to idTarget web server (http://idtarget.rcas.sinica.edu.tw/) (Wang et al., 2012). A 
dotted electrostatic surface was drawn around quercetin at a Van der Waals distance, areas depicted 
in red color correspond to a negative charged surface and white surface to a neutral charge. A good 
overlapping between naringenin a quercetin docking pose is observed confirming the reliability of 
the docking method. 
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Fig. 3. Structural alignment between ATP/ADP and quercetin given by SHAFTS (SHApe-Feature 
Similarity) algorithm (Liu et al., 2011). The alignment shows two different quercetin orientations 
(ATP alignment similarity score: 0.8693, ADP alignment similarity score: 0.9790) that can overlap 
functional groups of these endogenous ligands and suggests a quercetin ATP/ADP mimetic action. 
33 
Fig. 4. Comparison between idTarget docking score and MOE docking score.  For docking porpoise 
a single crystallographic structure representative of each protein was used in MOE. The score of the 
best ranking pose in MOE was compared against the best idTarget score. Orange dots: predicted 
targets, green dots: predicted and experimentally assayed targets. See Methods for further details. 
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Fig. 5. Protein-ligand interaction depictions of quercetin-target complexes by the end of molecular 
dynamics simulations (10 ns). Green circles represent greasy, purple circles represent polar, red 
circles represent acidic and blue circles represent basic amino acids. Protein contacts are depicted 
by a blue half moon around the amino acids. Blue arrows represent backbone acceptors; green ones 
depict side chain acceptors and side chain donors. Green benzol rings with a “+” describe an arene–
cation binding; 2 benzol rings, an arene–arene binding. Areas with a blue background are exposed 
to the ligand. The purple dotted lines represent metal contact (Clark and Labute, n.d.). 
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Fig. 6. STRING protein-protein interaction network analysis of target candidates. STRING database 
establishes functional associations between protein pairs based on documented experimental 
evidence, homology and text mining inference including protein modification, aggregation, 
genomic neighborhood and co-expression (Jensen et al., 2009). Only high confidence associations 
were depicted (0.7 probability and above). 
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